Tarceva Pancreatic Cancer sNDA Planned For 1H05; Avastin Combo To Follow
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Sponsors who plan to seek priority review status need to show a superior effect on clinical outcomes, an examination of priority review requests rejected by FDA suggests
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011